Financial results for the period ended Jun 30, 2026
As filed · CORONA Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
EarningsMajormateriality 77 out of 100
What happened
FactThe Board of Corona approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, based on the recommendation of the Audit Committee. The results, along with limited review reports, will be published in an advertisement and are available on the company's website. A press release regarding the financial results has also been submitted to the media.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- We continue to target 15% revenue growth and 20% PAT growth over the FY27. (management committed by FY27)
- Our FY27 guidance remains unchanged. We continue to target 15% organic revenue growth and about 1.5% to 2% ino (management committed by FY27)
Evidence
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%